Study on Plasmablastic Lymphoma Patients
ConditionPlasmablastic Lymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15+
SponsorFondazione Italiana Linfomi - ETS
About this trial
This is an observational, multicenter, international and retrospective study, that aims to collect data on clinical and pathological characteristics, treatment regimens, outcome, and prognostic factors (clinical, biomarkers and/or radio-metabolic) in patients affected by PBL.
Eligibility criteria
Qualifiers
Diagnosis of plasmablastic lymphoma (PBL) between Jan 1st 2000, and Dec 31st 2022
Histologically confirmed plasmablastic lymphoma (PBL) diagnosis according to local pathological report
Age > 18 years old
Availability of complete medical records
Disqualifiers
Any other histology than PBL
Lack of complete medical records
Lack of histopathological material requested by the study
Trial design
Treatments tested in this trial
- Not listed
Trial groups
200 Participants
are grouped into 1 trial groupSponsors and collaborators
Fondazione Italiana Linfomi - ETS
Lead sponsor
AIL Roma - Italia
Collaborator
AIL Cuneo - Italia
Collaborator
Source ClinicalTrials.gov